John Hainsworth, Ph.D.
Affiliations: | 2006 | Princeton University, Princeton, NJ |
Area:
Computer ScienceGoogle:
"John Hainsworth"Parents
Sign in to add mentor| Perry Cook | grad student | 2006 | Princeton | |
| (Enabling truly collaborative writing on a computer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Javle M, Borad MJ, Azad NS, et al. (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology |
| Yardley DA, Peacock N, Daniel B, et al. (2020) Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment |
| Spigel DR, Shipley DL, Waterhouse DM, et al. (2019) A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. The Oncologist |
| Hainsworth JD, Becker KP, Mekhail T, et al. (2019) Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). Journal of Neuro-Oncology |
| Hainsworth JD. (2019) Prolonging remission with rituximab maintenance therapy. Seminars in Oncology. 17-21 |
| Hainsworth JD. (2019) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. Seminars in Oncology. 29: 25-29 |
| Hainsworth JD, Vokes EE. (2019) Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Seminars in Oncology. 22-27 |
| Spigel DR, Burris HA, Greco FA, et al. (2018) Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer |
| Hainsworth JD, Waterhouse DM, Shih KC, et al. (2018) Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 118: 6-12 |
| Spigel DR, Hainsworth JD, Shipley DL, et al. (2018) Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer (Amsterdam, Netherlands). 117: 38-43 |